Cabozantinib (Cabometyx®)

Assessment Status NCPE Assessment process complete
Drug Cabozantinib
Brand Cabometyx®
Indication Treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
Assessment Process
Rapid review commissioned 20/03/2017
Rapid review completed 25/04/2017
Rapid review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 02/05/2017
Pre-submission consultation with Applicant 17/07/2017
Full submission received from Applicant 03/11/2017
Preliminary review sent to Applicant 24/01/2018
NCPE assessment re-commenced 27/04/2018
Factual accuracy sent to Applicant 06/06/2018
NCPE assessment re-commenced 29/06/2018
NCPE assessment completed 03/07/2018
NCPE assessment outcome The NCPE recommends that cabozantinib (Cabometyx®) for the treatment of advanced or metastatic clear-cell RCC not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations January 2019.

Technical Summary